Barclays downgraded shares of Myovant Sciences (NYSE:MYOV) from an overweight rating to an equal weight rating in a research note issued to investors on Thursday, Marketbeat reports. They currently have $18.00 price objective on the stock.
A number of other analysts have also commented on the company. ValuEngine raised Myovant Sciences from a sell rating to a hold rating in a research report on Wednesday. Zacks Investment Research lowered Myovant Sciences from a hold rating to a sell rating in a research report on Tuesday, February 20th. One research analyst has rated the stock with a sell rating, two have given a hold rating and four have given a buy rating to the stock. The stock presently has an average rating of Hold and a consensus target price of $21.00.
Shares of Myovant Sciences stock opened at $21.20 on Thursday. Myovant Sciences has a one year low of $9.92 and a one year high of $24.14. The company has a debt-to-equity ratio of 0.35, a current ratio of 5.04 and a quick ratio of 5.04.
In related news, major shareholder Pharmaceuticals Interna Takeda acquired 7,420,625 shares of the firm’s stock in a transaction on Monday, March 19th. The stock was purchased at an average cost of $18.67 per share, with a total value of $138,543,068.75. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, major shareholder Holdings Ltd. Dexxon acquired 1,110,015 shares of the firm’s stock in a transaction on Monday, April 2nd. The shares were bought at an average cost of $20.27 per share, with a total value of $22,500,004.05. The disclosure for this purchase can be found here. Insiders own 3.00% of the company’s stock.
A number of institutional investors and hedge funds have recently modified their holdings of MYOV. JPMorgan Chase & Co. increased its holdings in Myovant Sciences by 18.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 91,213 shares of the company’s stock worth $1,382,000 after purchasing an additional 14,203 shares in the last quarter. Point72 Asset Management L.P. bought a new stake in Myovant Sciences during the 3rd quarter worth approximately $1,255,000. Finally, Ardsley Advisory Partners bought a new stake in Myovant Sciences during the 4th quarter worth approximately $1,272,000. 81.44% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This piece of content was published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at https://www.tickerreport.com/banking-finance/3340945/myovant-sciences-myov-downgraded-by-barclays.html.
Myovant Sciences Company Profile
Myovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for women's health and endocrine diseases. The company's lead product is relugolix, an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone receptor antagonist, for the treatment of heavy menstrual bleeding related with uterine fibroids, endometriosis-associated pain, and advanced prostate cancer.
Receive News & Ratings for Myovant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myovant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.